Westminster Health Forum Keynote Seminar
Next steps for NICE: integration, medicine pricing and value based assessments
Morning, Thursday, 15th January 2015
Professor Gillian Leng, Deputy Chief Executive and Director of Health and Social Care, NICE; Paul Catchpole, Director of Value and Access, ABPI; Dr Sunjai Gupta, Consultant and Senior Scientific Advisor, Health and Wellbeing Directorate, Public Health England; Dr Zahid Latif, Head of Healthcare, Technology Strategy Board and Professor Allan Wailoo, Professor of Health Economics, University of Sheffield and Director, NICE Decision Support Unit and Omar Ali, Surrey and Sussex Healthcare NHS Trust; Dr Sheila Hardy, UCL Partners; Dr Naz Jivani, NHS Kingston Clinical Commissioning Group; Andy Pike, RNIB and Miles Scott, St. George’s Healthcare NHS Trust
“Delegates at this timely seminar will discuss priorities for NICE for the year ahead, and challenges for implementing value based assessments.
With the Pharmaceutical Price Regulation Scheme (PPRS) for 2014-18 including provision for a more innovative perspective in the adoption of new medicines, delegates will consider what impact value based assessments will have on NHS providers, the pharmaceutical industry, and on patient outcomes and access to new treatments.
Sessions will also focus on the challenges of measuring value – including the burden of illness and wider societal impact – and the role of NICE and other key partners in encouraging innovation more widely.
The development of new NICE standards and pathways across health, public health and social care, including the latest Quality and Outcomes Framework (QOF), safe staffing levels, and patient experience and safety will also be examined.
Overall, areas for discussion include:
• Priorities for NICE in health and social care;
• Challenges for commissioning, integration and setting public health standards;
• Progress on developing and implementing NICE guidance on safe staffing;
• The role of new technologies in accelerating innovation in healthcare;
• Next steps for the pharmaceutical industry following the introduction of the PPRS; and
• Early indications on the new value based assessment system.
More information at: